Abstract:Objective: To observe of clinical efficacy of Qingre Huoxue Sanjie Chinese medicine compound against radiation pneumonitis,pulmonary fibrosis and its effect on serum cytokines interleukin-6(IL-6), tumor necrosis factor-α(TNF-α),transforming growth factor-β1 (TGF-β1)level. Method: Using propective randomized controlled design,patients eligible were randomly divided into a treatment group and a control group, each of 62 cases. The controlled group was only treated with radiotherapy,the treatment group was treated radiotherapy plus oral Chinese medicine. Before and after treatment,the patients's general condition, clinical manifestations, chest CT, lung injury (RTOG criteria) were evaluated as indicators for clinical efficacy observation,and using karnofsky performance status scale(KPS) for performance evaluation, serum cytokines IL-6,TNF-α,TGF-β1 levels were tested respectively. Result: The two groups were no loss and excluding cases, no significant differences in baseline data (P>0.05);after treatment, compared with the control group, the treatment group was able to significantly improve patients karnofsky ratings,RTOG rating evaluation of improvement in the treatment of lung injury is significantly better than the control group (P<0.05),the treatment group of radiation pneumonitis and pulmonary fibrosis prevalence was lower than controlled group(38.71% vs 72.58%,P<0.05);two groups of serum IL-6,TNF-α,TGF-β1 level had no significant diference before treatment;at the end of radiotherapy and six months after radiotherapy, the serum IL-6,TNF-α,TGF-β1 were both significantly lower than before treatment respectively (P<0.01), and the serum IL-6,TNF-α,TGF-β1 level all reached the peak at the end of radiotherapy. Conclusion: Qingre Huoxue Sanje Chinese medicine compound was safe and effective,which can lower prevalence of radiation pneumonitis and pulmonary fibrosis,and can alleviate the symptoms of patients,improve the quality of life,its mechanism maybe related with reducing serum IL-6,TNF-α,TGF-β1 levels of radiation pneumonitis and pulmonary fibrosis patients.
